ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,171.12
0.61%
Dow Jones
39,308.00
-0.06%
Gold vs US Dollar
2,355.725
1.09%
Brent Oil
86.38
-0.08%
Bitcoin
60,394.99
-2.63%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Neurogene Inc (NGNE) Share Price

NGNE Neurogene Inc

36.10
-2.36 (-6.14%)
Last Updated: 17:59:35
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Neurogene Inc NASDAQ:NGNE NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   -2.36 -6.14 36.10 35.95 36.25 39.00 36.06 38.41 68,900 16:59:35   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Pharmaceutical Preparations  -36.32M -2.7979 -1.25 45.3M
 Type  Size  Price  Time  Units 
 9 2 36.10 16:59:36 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore NGNE News
02/07/202412:30BWNeurogene to Participate in BMO Genetic Medicines Summit
01/07/202412:30BWNeurogene Announces Addition to Russell 3000® Index
18/06/202414:26BWNeurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
05/06/202412:30BWNeurogene to Participate in Upcoming Conferences
03/06/202412:30BWNeurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program
10/05/202412:30BWNeurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates
07/05/202411:19BWNeurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting
Period
Draw mode
Data Downloads for NGNE

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Neurogene Inc Articles